Show all
Ultromics receive $10m funding to accelerate innovation and growth for EchoGo. Read more here.
Learn more about how tools like EchoGo can provide off-cart analysis and diagnosis that can enhance workflow efficiencies and reduce exposure to COVID.
Mayo Clinic has collaborated with Ultromics to rapidly assess patients diagnosed with COVID-19. Read more about the collaboration here.
Ultromics CE marked its automated coronary artery disease prediction system, EchoGo Pro, allowing it to be used commercially across the UK and the EU.
Ultromics has achieved the ISO 27001 certification. Read more about Ultromics and our innovative AI solutions here.
Ultromics has received FDA clearance for its AI-powered decision support system, EchoGo Core. Read more about it here.
Researchers at an Oxford hospital have developed an artificial intelligence (AI) that can diagnose scans for heart disease and lung cancer.
Ultromics is now a founding partner of AI centre of excellence. Read more about how AI can make an impact in patient outcomes.
Learn more about how Ultromics is expanding coronary artery disease trials to the U.S.
Ultromics has secured additional £1m investment from Woodford Investment Management. Read more about Ultromics and our innovative AI solutions here.
Ultromics has secured £10 million investment to bring AI heart diagnostics to hospitals. Read more about our innovative AI solutions here.
Sign-up to hear about the latest news.
Sign up to newsletter
cases processed
